The 2024 Global Patient Survey on Lymphomas & CLL captured a comprehensive overview of the experiences of 11,170 patients and care partners from 79 countries across the world. This biennial survey offers critical insights into diagnosis, treatment, and the emotional and physical challenges faced by those living with lymphoma and CLL.
The goal behind the GPS is to truly understand the current voices and values of adult patients and care partners. Lymphoma Coalition is in a stronger position to do this work, as a result of the support and engagement from our Member organisations, along with scientific partners, healthcare providers and community alliances. The hard work at the regional and local level ensures the voices of as many people as possible from around the world are heard through the data that is captured in the GPS.
The 2024 Global Report is a longer-form report that goes into detail with the various datasets, using figures, which help to highlight the results across the various categories, leveraging a truly global perspective. While the 2024 Highlights Report is a much shorter report which summarises the key findings related to trends in patient care, shared decision-making, and barriers to treatment, aiming to enhance understanding and support for the global lymphoma community.
Why do we do this research?
Lymphoma Coalition is committed to bringing equity in lymphoma across borders. To do this, we must accurately represent the current voices and values of patients and their caregivers when we work with healthcare professionals, researchers, industry and others. This knowledge is gathered through the Global Patient Survey.
In addition, the results of past surveys have been used to inform published research papers, conference presentations and posters, patient resources, education materials and World Lymphoma Awareness Campaigns. The results of the GPS are shared in a Global Report, as well as regional reports.
When 100 or more participants complete the survey from one country, a Country Report is created that highlights the findings, which can be used for local planning to ensure activities align with patients’ needs, as well as other advocacy efforts as needed. In addition, Lymphoma Coalition can support member organisations with data needs for therapy approvals.
It is through partnership with member organisations that we can successfully gather the experiences and insights of patients and caregivers around the world.
Past Surveys
In 2022, the GPS was redesigned to include patient and caregiver-specific questions, expanded questions on healthcare information, involvement and decision-making, and new questions on the impact of Covid-19. Member organisations in countries with 100+ responses to the previous survey (LC 2020 GPS) were invited to add up to five additional country-specific questions that addressed their local issues and concerns. Two subtype-specific member organisations had the same invitation.
The results in this report present the data from all worldwide respondents. The overall number of completed responses was 8637, made up of:
7113 Patients 1524 Caregivers
The 2020 GPS had two streams – one for patients and one for caregivers. There was an excellent response, with 11,878 responses globally comprised of 9,179 patients and 2,699 caregivers. 18 countries had over 100 responses, and member organisations within these countries are provided with this data to help them in their own planning and advocacy work. Separate reports were also created for cutaneous lymphomas, chronic lymphocytic leukaemia (CLL) and Waldenstrom’s macroglobulinemia.
To review results from past year’s surveys, please contact the Marketing Coordinator.
